Publications
61
Citations
1,376
Est. group size
—
Recurring co-author estimate
Active years
6
Publishing since 2020
Louise Ferrall works in medical research focused on human papillomavirus (HPV) and cervical cancer, particularly the development of therapeutic vaccines to treat HPV infections and precancerous cervical lesions. This includes designing DNA and protein-based vaccine strategies and building laboratory mouse models to study how HPV-driven cancers develop. The work spans early-stage clinical safety studies as well as broader questions in immunotherapy and reproductive health.
Publication activity began around 2020 and grew to a peak in 2023, with fewer outputs recorded in 2024–2025.
Generated by claude-opus-4-8 from public bibliographic data · Jul 11, 2026
- Supplementary Table S4 from Safety Run-in of Intramuscular pNGVL4a-Sig/E7(detox)/HSP70 DNA and TA-CIN Protein Vaccination as Treatment for HPV16+ ASC-US, ASC-H, or LSIL/CIN1
2025
- Supplementary Table S5 from Safety Run-in of Intramuscular pNGVL4a-Sig/E7(detox)/HSP70 DNA and TA-CIN Protein Vaccination as Treatment for HPV16+ ASC-US, ASC-H, or LSIL/CIN1
2025
- Supplementary Table S1 from Safety Run-in of Intramuscular pNGVL4a-Sig/E7(detox)/HSP70 DNA and TA-CIN Protein Vaccination as Treatment for HPV16+ ASC-US, ASC-H, or LSIL/CIN1
2025
- Supplementary Table S3 from Safety Run-in of Intramuscular pNGVL4a-Sig/E7(detox)/HSP70 DNA and TA-CIN Protein Vaccination as Treatment for HPV16+ ASC-US, ASC-H, or LSIL/CIN1
2025
- Supplementary Table S2 from Safety Run-in of Intramuscular pNGVL4a-Sig/E7(detox)/HSP70 DNA and TA-CIN Protein Vaccination as Treatment for HPV16+ ASC-US, ASC-H, or LSIL/CIN1
2025
- The Opaque Womb: Unraveling Gendered and Individualist Underpinnings in the History of Maternal-Fetal Effects and Epigenetics Research
Women s Reproductive Health · 2024
- Supplementary Table S3 from Safety Run-in of Intramuscular pNGVL4a-Sig/E7(detox)/HSP70 DNA and TA-CIN Protein Vaccination as Treatment for HPV16+ ASC-US, ASC-H, or LSIL/CIN1
2023
- Supplementary Table S5 from Safety Run-in of Intramuscular pNGVL4a-Sig/E7(detox)/HSP70 DNA and TA-CIN Protein Vaccination as Treatment for HPV16+ ASC-US, ASC-H, or LSIL/CIN1
2023
- Supplementary Table S2 from Safety Run-in of Intramuscular pNGVL4a-Sig/E7(detox)/HSP70 DNA and TA-CIN Protein Vaccination as Treatment for HPV16+ ASC-US, ASC-H, or LSIL/CIN1
2023
- Supplementary Table S1 from Safety Run-in of Intramuscular pNGVL4a-Sig/E7(detox)/HSP70 DNA and TA-CIN Protein Vaccination as Treatment for HPV16+ ASC-US, ASC-H, or LSIL/CIN1
2023
- Supplementary Table S4 from Safety Run-in of Intramuscular pNGVL4a-Sig/E7(detox)/HSP70 DNA and TA-CIN Protein Vaccination as Treatment for HPV16+ ASC-US, ASC-H, or LSIL/CIN1
2023
- Supplementary Table S5 from Safety Run-in of Intramuscular pNGVL4a-Sig/E7(detox)/HSP70 DNA and TA-CIN Protein Vaccination as Treatment for HPV16+ ASC-US, ASC-H, or LSIL/CIN1
2023
- Supplementary Table S1 from Safety Run-in of Intramuscular pNGVL4a-Sig/E7(detox)/HSP70 DNA and TA-CIN Protein Vaccination as Treatment for HPV16+ ASC-US, ASC-H, or LSIL/CIN1
2023
- Supplementary Table S4 from Safety Run-in of Intramuscular pNGVL4a-Sig/E7(detox)/HSP70 DNA and TA-CIN Protein Vaccination as Treatment for HPV16+ ASC-US, ASC-H, or LSIL/CIN1
2023
- Supplementary Table S3 from Safety Run-in of Intramuscular pNGVL4a-Sig/E7(detox)/HSP70 DNA and TA-CIN Protein Vaccination as Treatment for HPV16+ ASC-US, ASC-H, or LSIL/CIN1
2023
- Journal of Biomedical Science×5
- Figshare×4
- mBio×3
- Menopause The Journal of The North American Menopause Society×2
- Clinical Cancer Research×1
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 11, 2026.
Claim or correct this profile